{"protocolSection":{"identificationModule":{"nctId":"NCT04476030","orgStudyIdInfo":{"id":"217-MDD-305"},"organization":{"fullName":"Biogen","class":"INDUSTRY"},"briefTitle":"A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder","officialTitle":"A Phase 3, Randomized, Double-Blind Study Comparing the Efficacy and Safety of SAGE-217 Plus an Antidepressant Versus Placebo Plus an Antidepressant in Adults With Major Depressive Disorder"},"statusModule":{"statusVerifiedDate":"2023-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-11-09","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-10-25","type":"ACTUAL"},"completionDateStruct":{"date":"2021-12-22","type":"ACTUAL"},"studyFirstSubmitDate":"2020-07-15","studyFirstSubmitQcDate":"2020-07-15","studyFirstPostDateStruct":{"date":"2020-07-17","type":"ACTUAL"},"resultsFirstSubmitDate":"2023-08-25","resultsFirstSubmitQcDate":"2023-10-13","resultsFirstPostDateStruct":{"date":"2023-11-07","type":"ACTUAL"},"dispFirstSubmitDate":"2022-11-30","dispFirstPostDateStruct":{"date":"2023-11-07","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-12-20","lastUpdatePostDateStruct":{"date":"2023-12-22","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Biogen","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"The primary purpose of this study is to evaluate the efficacy of SAGE-217 plus an ADT in the treatment of major depressive disorder (MDD) compared to placebo plus an ADT.","detailedDescription":"This study was previously posted by Sage Therapeutics. In November 2023, sponsorship of the trial was transferred to Biogen."},"conditionsModule":{"conditions":["Depressive Disorder, Major"],"keywords":["Major Depressive Disorder","MDD","SAGE-217"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":440,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo + Assigned ADT","type":"ACTIVE_COMPARATOR","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42.","interventionNames":["Drug: Matching Placebo","Drug: Sertraline","Drug: Escitalopram","Drug: Citalopram","Drug: Duloxetine","Drug: Desvenlafaxine"]},{"label":"SAGE-217 + Assigned ADT","type":"EXPERIMENTAL","description":"Participants received SAGE-217, 50 milligrams (mg), orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42.","interventionNames":["Drug: SAGE-217","Drug: Sertraline","Drug: Escitalopram","Drug: Citalopram","Drug: Duloxetine","Drug: Desvenlafaxine"]}],"interventions":[{"type":"DRUG","name":"SAGE-217","description":"Oral capsules","armGroupLabels":["SAGE-217 + Assigned ADT"]},{"type":"DRUG","name":"Matching Placebo","description":"Oral capsules","armGroupLabels":["Placebo + Assigned ADT"]},{"type":"DRUG","name":"Sertraline","description":"Oral tablets","armGroupLabels":["Placebo + Assigned ADT","SAGE-217 + Assigned ADT"]},{"type":"DRUG","name":"Escitalopram","description":"Oral tablets","armGroupLabels":["Placebo + Assigned ADT","SAGE-217 + Assigned ADT"]},{"type":"DRUG","name":"Citalopram","description":"Oral tablets","armGroupLabels":["Placebo + Assigned ADT","SAGE-217 + Assigned ADT"]},{"type":"DRUG","name":"Duloxetine","description":"Oral capsules","armGroupLabels":["Placebo + Assigned ADT","SAGE-217 + Assigned ADT"]},{"type":"DRUG","name":"Desvenlafaxine","description":"Oral tablets","armGroupLabels":["Placebo + Assigned ADT","SAGE-217 + Assigned ADT"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in the HAMD-17 Total Score at Day 3","description":"The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. A negative change from baseline indicated improvement. Least Squares (LS) mean was estimated using mixed effects model for repeated measures (MMRM) analysis.","timeFrame":"Baseline, Day 3"}],"secondaryOutcomes":[{"measure":"Change From Baseline in the HAMD-17 Total Score Over the Double-Blind Treatment Period","description":"The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. A negative change from baseline indicated improvement. LS mean was estimated using MMRM analysis. The data reported is summary of data collected and analyzed during double-blind treatment period at Baseline, Day 3, Day 8, Day 12, and Day 15 using equal weights for the scheduled visits.","timeFrame":"Baseline through Day 15"},{"measure":"Change From Baseline in the HAMD-17 Total Score at Days 15 and 42","description":"The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. A negative change from baseline indicated improvement. LS mean was estimated using MMRM analysis. The missing values were imputed for the analysis.","timeFrame":"Baseline, Days 15 and 42"},{"measure":"Change From Baseline in the HAMD-17 Total Score Around End of Blinded Treatment","description":"The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. A negative change from baseline indicated improvement. End of blinded treatment was defined as the average of change from baseline values of Days 12, 15 and 18. LS mean was estimated using MMRM analysis.","timeFrame":"Baseline, End of blinded treatment assessment (i.e., average of Days 12, 15 , and 18)"},{"measure":"Percentage of Participants With HAMD-17 Response at Day 15 and Day 42","description":"HAM-D response was defined as having a 50% or greater reduction from baseline in HAM-D total score. The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. Percentages were rounded off to the first decimal point.","timeFrame":"At Days 15 and 42"},{"measure":"Percentage of Participants With HAMD-17 Remission at Day 15 and Day 42","description":"HAM-D remission was defined as having a HAM-D total score of ≤7. The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. Percentages were rounded off to the first decimal point.","timeFrame":"Days 15 and 42"},{"measure":"Change From Baseline in CGI-S Score at Day 15","description":"The CGI-S uses a 7-point Likert scale to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis. Considering total clinical experience, the investigator rated the participant on severity of mental illness at the time of rating as: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = extremely ill. A higher score indicated extreme illness. A negative change from baseline indicated improvement. LS mean was estimated using MMRM analysis.","timeFrame":"Baseline and Day 15"},{"measure":"Percentage of Participants With CGI-I Response, at Day 3 and Day 15","description":"CGI-I response was defined as having a CGI-I score of \"very much improved\" or \"much improved.\" The CGI-I employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to IP. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. By definition, all CGI-I assessments are evaluated against baseline conditions. Higher scores indicated worse condition. Percentages were rounded off to the first decimal point.","timeFrame":"Days 3 and 15"},{"measure":"Change From Baseline in MADRS Total Score at Day 15","description":"The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS total score was calculated as the sum of the 10 individual item scores. Each item yields a score of 0 (no symptoms) to 6 (symptoms of maximum severity). The total MADRS score (sum of all individual items) ranges from 0 (symptoms absent) to 60 (severe depression). Higher MADRS scores indicated more severe depression. A negative change from baseline indicated improvement. LS mean was estimated using MMRM analysis.","timeFrame":"Baseline and Day 15"},{"measure":"Percentage of Participants With MADRS Response at Day 15","description":"MADRS response was defined as having a 50% or greater reduction from baseline in MADRS total score. The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS total score was calculated as the sum of the 10 individual item scores. Each item yields a score of 0 (no symptoms) to 6 (symptoms of maximum severity). The total MADRS score (sum of all individual items) ranges from 0 (symptoms absent) to 60 (severe depression). Higher MADRS scores indicated more severe depression. Percentages were rounded off to the first decimal point.","timeFrame":"Day 15"},{"measure":"Percentage of Participants With MADRS Remission at Day 15","description":"MADRS remission was defined as having a MADRS total score of ≤10. The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS total score was calculated as the sum of the 10 individual item scores. Each item yields a score of 0 (no symptoms) to 6 (symptoms of maximum severity). The total MADRS score (sum of all individual items) ranges from 0 (symptoms absent) to 60 (severe depression). Higher MADRS scores indicated more severe depression. Percentages were rounded off to the first decimal point.","timeFrame":"Day 15"},{"measure":"Change From Baseline in HAM-A Total Score at Day 15","description":"Each of the 14 items in the HAM-A was defined by a series of symptoms, and measured both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints). The HAM-A total score was calculated as sum of the 14 individual item scores, each rated on a five point scale ranging from 0 (not present) to 4 (very severe). The total score (sum of all individual items) range from 0 to 56, where \\<17 indicated mild severity, 18 to 24 indicated mild to moderate severity, and 25 to 30 indicated moderate to severe severity. Higher scores indicated more severe disease. Negative change from baseline indicated improvement. LS mean was estimated using MMRM analysis.","timeFrame":"Baseline, Day 15"},{"measure":"Time to First HAMD-17 Response","description":"HAM-D response was defined as having a 50% or greater reduction from baseline in HAM-D total score. The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. Time (in days) from first dose of study drug to time of first HAMD response was reported in this outcome measure.","timeFrame":"From first dose of study drug up to first HAMD-17 response (up to approximately 65 days)"},{"measure":"Change From Baseline in Depressive Symptoms at Day 15, as Assessed by PHQ-9","description":"The PHQ-9 is a participant-rated depressive symptom severity scale. The PHQ-9 total score is calculated as the sum of the 9 individual item scores. For individual items, scoring is based on responses to specific questions, as follows: 0 = not at all; 1 = several days; 2 = more than half the days; and 3 = nearly every day. The PHQ-9 possible total score range is 0 to 27, with higher scores reflecting greater depressive symptoms, and is categorized as follows: 0 to 4 = minimal depression, 5 to 9 = mild depression, 10 to 14 = moderate depression, 15 to 19 = moderately severe depression, and 20 to 27 = severe depression. Negative change from baseline indicated improvement. LS mean was estimated using MMRM analysis.","timeFrame":"Baseline and Day 15"},{"measure":"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)","description":"An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE was defined as an AE with onset after the start of IP, or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study.","timeFrame":"Up to approximately 58 weeks"},{"measure":"Percentage of Participants With TEAEs, Graded by Severity","description":"An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE was defined as an AE with onset after the start of IP, or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study. The severity was graded as mild, moderate and severe.","timeFrame":"Up to approximately 58 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of MDD as diagnosed by Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Clinical Trials Version (SCID-5-CT), with symptoms that have been present for at least a 4-week period\n* 17-item Hamilton Rating Scale for Depression (HAM-D-17) total score of ≥24 at Screening and Day 1\n* Participant in good physical health and has no clinically significant findings, as determined by the investigator, on physical examination, 12-lead electrocardiogram (ECG), or clinical laboratory tests\n* Participant is willing, able, and eligible to take at least 1 of the 5 ADTs specified in the protocol (an eligible ADT is an ADT that has not been taken during the current depressive episode and for which the participant has no contraindications; further, a participant is not eligible for citalopram if escitalopram has been taken during the current depressive episode, and vice versa)\n\nExclusion Criteria:\n\n* Has attempted suicide associated with the current episode of MDD\n* Participant had onset of the current depressive episode during pregnancy or 4 weeks postpartum, or the participant has presented for screening during the 6-month postpartum period\n* Participant has treatment-resistant depression\n* History of bipolar disorder, schizophrenia, and/or schizoaffective disorder\n* Known allergy to SAGE-217, allopregnanolone, or related compounds\n* Has taken antidepressants within 30 days prior to Day 1, and/or has taken fluoxetine within 60 days prior to Day 1","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Sage Investigational Site","city":"Dothan","state":"Alabama","zip":"36303","country":"United States","geoPoint":{"lat":31.22323,"lon":-85.39049}},{"facility":"Sage Investigational Site","city":"Phoenix","state":"Arizona","zip":"85012","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Sage Investigational Site","city":"Anaheim","state":"California","zip":"92805","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"Sage Investigational Site","city":"Costa Mesa","state":"California","zip":"92626","country":"United States","geoPoint":{"lat":33.64113,"lon":-117.91867}},{"facility":"Sage Investigational Site","city":"Glendale","state":"California","zip":"91206","country":"United States","geoPoint":{"lat":34.14251,"lon":-118.25508}},{"facility":"Sage Investigational Site","city":"Irvine","state":"California","zip":"92614","country":"United States","geoPoint":{"lat":33.66946,"lon":-117.82311}},{"facility":"Sage Investigational Site","city":"Los Alamitos","state":"California","zip":"90720","country":"United States","geoPoint":{"lat":33.80307,"lon":-118.07256}},{"facility":"Sage Investigational Site","city":"Oceanside","state":"California","zip":"92056","country":"United States","geoPoint":{"lat":33.19587,"lon":-117.37948}},{"facility":"Sage Investigational Site","city":"Orange","state":"California","zip":"92868","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}},{"facility":"Sage Investigational Site","city":"Riverside","state":"California","zip":"92503","country":"United States","geoPoint":{"lat":33.95335,"lon":-117.39616}},{"facility":"Sage Investigational Site","city":"San Diego","state":"California","zip":"92103","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Sage Investigational Site","city":"Temecula","state":"California","zip":"92591","country":"United States","geoPoint":{"lat":33.49364,"lon":-117.14836}},{"facility":"Sage Investigational Site","city":"Colorado Springs","state":"Colorado","zip":"80910","country":"United States","geoPoint":{"lat":38.83388,"lon":-104.82136}},{"facility":"Sage Investigational Site","city":"Cromwell","state":"Connecticut","zip":"06416","country":"United States","geoPoint":{"lat":41.5951,"lon":-72.64537}},{"facility":"Sage Investigational Site","city":"Norwich","state":"Connecticut","zip":"06360","country":"United States","geoPoint":{"lat":41.52426,"lon":-72.07591}},{"facility":"Sage Investigational Site","city":"Coral Springs","state":"Florida","zip":"33067","country":"United States","geoPoint":{"lat":26.27119,"lon":-80.2706}},{"facility":"Sage Investigational Site","city":"Jacksonville","state":"Florida","zip":"32256","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Sage Investigational Site","city":"Orlando","state":"Florida","zip":"32801","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Sage Investigational Site","city":"Orlando","state":"Florida","zip":"32807","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Sage Investigational Site","city":"Pensacola","state":"Florida","zip":"32502","country":"United States","geoPoint":{"lat":30.42131,"lon":-87.21691}},{"facility":"Sage Investigational Site","city":"Alpharetta","state":"Georgia","zip":"30022","country":"United States","geoPoint":{"lat":34.07538,"lon":-84.29409}},{"facility":"Sage Investigational Site","city":"Atlanta","state":"Georgia","zip":"30331","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Sage Investigational Site","city":"Marietta","state":"Georgia","zip":"30060","country":"United States","geoPoint":{"lat":33.9526,"lon":-84.54993}},{"facility":"Sage Investigational Site","city":"Savannah","state":"Georgia","zip":"31405","country":"United States","geoPoint":{"lat":32.08354,"lon":-81.09983}},{"facility":"Sage Investigational Site","city":"Chicago","state":"Illinois","zip":"60634","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Sage Investigational Site","city":"Chicago","state":"Illinois","zip":"60640","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Sage Investigational Site","city":"Towson","state":"Maryland","zip":"21204","country":"United States","geoPoint":{"lat":39.4015,"lon":-76.60191}},{"facility":"Sage Investigational Site","city":"Watertown","state":"Massachusetts","zip":"02472","country":"United States","geoPoint":{"lat":42.37093,"lon":-71.18283}},{"facility":"Sage Investigational Site","city":"Ann Arbor","state":"Michigan","zip":"48109","country":"United States","geoPoint":{"lat":42.27756,"lon":-83.74088}},{"facility":"Sage Investigational Site","city":"Saint Charles","state":"Missouri","zip":"63304","country":"United States","geoPoint":{"lat":38.78394,"lon":-90.48123}},{"facility":"Sage Investigational Site","city":"Lincoln","state":"Nebraska","zip":"68526","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}},{"facility":"Sage Investigational Site","city":"Cherry Hill","state":"New Jersey","zip":"08002","country":"United States","geoPoint":{"lat":39.93484,"lon":-75.03073}},{"facility":"Sage Investigational Site","city":"Marlton","state":"New Jersey","zip":"08053","country":"United States","geoPoint":{"lat":39.89122,"lon":-74.92183}},{"facility":"Sage Investigational Site","city":"Princeton","state":"New Jersey","zip":"08540","country":"United States","geoPoint":{"lat":40.34872,"lon":-74.65905}},{"facility":"Sage Investigational Site","city":"Albuquerque","state":"New Mexico","zip":"87109","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"facility":"Sage Investigational Site","city":"Brooklyn","state":"New York","zip":"11229","country":"United States","geoPoint":{"lat":40.6501,"lon":-73.94958}},{"facility":"Sage Investigational Site","city":"Brooklyn","state":"New York","zip":"11235","country":"United States","geoPoint":{"lat":40.6501,"lon":-73.94958}},{"facility":"Sage Investigational Site","city":"Mount Kisco","state":"New York","zip":"10549","country":"United States","geoPoint":{"lat":41.20426,"lon":-73.72708}},{"facility":"Sage Investigational Site","city":"Beachwood","state":"Ohio","zip":"44122","country":"United States","geoPoint":{"lat":41.4645,"lon":-81.50873}},{"facility":"Sage Investigational Site","city":"Cincinnati","state":"Ohio","zip":"45212","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Sage Investigational Site","city":"Cincinnati","state":"Ohio","zip":"45215","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Sage Investigational Site","city":"Cincinnati","state":"Ohio","zip":"45219","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Sage Investigational Site","city":"North Canton","state":"Ohio","zip":"44720","country":"United States","geoPoint":{"lat":40.87589,"lon":-81.40234}},{"facility":"Sage Investigational Site","city":"Oklahoma City","state":"Oklahoma","zip":"73112","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Sage Investigational Site","city":"Plymouth Meeting","state":"Pennsylvania","zip":"19462","country":"United States","geoPoint":{"lat":40.10233,"lon":-75.27435}},{"facility":"Sage Investigational Site","city":"Austin","state":"Texas","zip":"78759","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Sage Investigational Site","city":"Dallas","state":"Texas","zip":"75231","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Sage Investigational Site","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Sage Investigational Site","city":"Houston","state":"Texas","zip":"77081","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Sage Investigational Site","city":"Wichita Falls","state":"Texas","zip":"76309","country":"United States","geoPoint":{"lat":33.91371,"lon":-98.49339}},{"facility":"Sage Investigational Site","city":"Bellevue","state":"Washington","zip":"98007","country":"United States","geoPoint":{"lat":47.61038,"lon":-122.20068}}]},"referencesModule":{"references":[{"pmid":"37875578","type":"DERIVED","citation":"Parikh SV, Aaronson ST, Mathew SJ, Alva G, DeBattista C, Kanes S, Lasser R, Bullock A, Kotecha M, Jung J, Forrestal F, Jonas J, Vera T, Leclair B, Doherty J. Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study. Neuropsychopharmacology. 2024 Jan;49(2):467-475. doi: 10.1038/s41386-023-01751-9. Epub 2023 Oct 24."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/","url":"https://vivli.org/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 440 participants were enrolled in the study of which 430 participants received at least 1 dose of the assigned treatment. The study consisted of a 28-day Screening period, a 14-day Double-blind Treatment Period, and a 28-day antidepressant therapy (ADT) continuation period.","recruitmentDetails":"Participants took part in the study at 53 investigative sites in the United States from 9 November 2020 to 22 December 2021.","groups":[{"id":"FG000","title":"Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"FG001","title":"SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 milligrams (mg), orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"220"},{"groupId":"FG001","numSubjects":"220"}]},{"type":"Safety Population","comment":"Safety Set included all participants who administered blinded IP.","achievements":[{"groupId":"FG000","numSubjects":"218"},{"groupId":"FG001","numSubjects":"212"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"177"},{"groupId":"FG001","numSubjects":"180"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"43"},{"groupId":"FG001","numSubjects":"40"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"16"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"11"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"4"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Protocol Deviation","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Non-compliance with Investigational Product (IP)","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Randomized but not Dosed","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"8"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety Set included all participants who administered blinded IP.","groups":[{"id":"BG000","title":"Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"BG001","title":"SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 mg, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"218"},{"groupId":"BG001","value":"212"},{"groupId":"BG002","value":"430"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"37.7","spread":"12.28"},{"groupId":"BG001","value":"38.6","spread":"12.72"},{"groupId":"BG002","value":"38.1","spread":"12.49"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"140"},{"groupId":"BG001","value":"129"},{"groupId":"BG002","value":"269"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"78"},{"groupId":"BG001","value":"83"},{"groupId":"BG002","value":"161"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"93"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"166"},{"groupId":"BG001","value":"171"},{"groupId":"BG002","value":"337"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"168"},{"groupId":"BG001","value":"153"},{"groupId":"BG002","value":"321"}]}]},{"title":"Black or African-American","categories":[{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"77"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"18"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}]},{"title":"More than one race","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}]}]},{"title":"American-Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]},{"title":"Native Hawaiian or Other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}]}]},{"title":"17-item Hamilton Rating Scale for Depression (HAMD-17) Total Score","description":"The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"score on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26.6","spread":"2.58"},{"groupId":"BG001","value":"26.8","spread":"2.51"},{"groupId":"BG002","value":"26.7","spread":"2.54"}]}]}]},{"title":"Clinical Global Impression - Severity (CGI-S) Score","description":"The CGI-S uses a 7-point Likert scale to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis. Considering total clinical experience, the investigator rated the participant on severity of mental illness at the time of rating as: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = extremely ill. A higher score indicated extreme illness.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"score on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4.9","spread":"0.57"},{"groupId":"BG001","value":"5.0","spread":"0.54"},{"groupId":"BG002","value":"4.9","spread":"0.55"}]}]}]},{"title":"Hamilton Anxiety Rating Scale (HAM-A) Total Score","description":"Each of the 14 items in the HAM-A was defined by a series of symptoms, and measured both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints). The HAM-A total score was calculated as sum of the 14 individual item scores, each rated on a five point scale ranging from 0 (not present) to 4 (very severe). The total score (sum of all individual items) range from 0 to 56, where \\<17 indicated mild severity, 18 to 24 indicated mild to moderate severity, and 25 to 30 indicated moderate to severe severity. Higher scores indicated more severe disease.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"score on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20.4","spread":"5.80"},{"groupId":"BG001","value":"19.9","spread":"5.28"},{"groupId":"BG002","value":"20.1","spread":"5.55"}]}]}]},{"title":"Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score","description":"The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS total score was calculated as the sum of the 10 individual item scores. Each item yields a score of 0 (no symptoms) to 6 (symptoms of maximum severity). The total MADRS score (sum of all individual items) ranges from 0 (symptoms absent) to 60 (severe depression). Higher MADRS scores indicated more severe depression.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"score on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"34.9","spread":"4.89"},{"groupId":"BG001","value":"35.2","spread":"4.70"},{"groupId":"BG002","value":"35.0","spread":"4.80"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in the HAMD-17 Total Score at Day 3","description":"The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. A negative change from baseline indicated improvement. Least Squares (LS) mean was estimated using mixed effects model for repeated measures (MMRM) analysis.","populationDescription":"Full analysis set included all randomized participants who administered blinded IP with a valid baseline total score and at least 1 valid postbaseline total score in at least 1 of HAMD-17, HAM-A, MADRS, 9-item Patient Health Questionnaire (PHQ-9) or had a valid baseline and at least 1 valid postbaseline value in at least 1 of CGI-S or Clinical Global Impression - Improvement (CGI-I) score. Overall number of participants analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Day 3","groups":[{"id":"OG000","title":"Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"OG001","title":"SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 mg, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"204"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.0","spread":"0.38"},{"groupId":"OG001","value":"-8.9","spread":"0.39"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0004","statisticalMethod":"MMRM","paramType":"LS Mean Difference","paramValue":"-1.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.0","ciUpperLimit":"-0.9","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.55","estimateComment":"Model used was the MMRM with treatment, baseline HAMD-17 total score, antidepressant use (SSRI/SNRI), assessment time point, and time point-by-treatment interaction as fixed effects with unstructured covariance structure."}]},{"type":"SECONDARY","title":"Change From Baseline in the HAMD-17 Total Score Over the Double-Blind Treatment Period","description":"The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. A negative change from baseline indicated improvement. LS mean was estimated using MMRM analysis. The data reported is summary of data collected and analyzed during double-blind treatment period at Baseline, Day 3, Day 8, Day 12, and Day 15 using equal weights for the scheduled visits.","populationDescription":"Full analysis set included all randomized participants who administered blinded IP with a valid baseline total score and at least 1 valid postbaseline total score in at least 1 of HAMD-17, HAM-A, MADRS, PHQ-9 or had a valid baseline and at least 1 valid postbaseline value in at least 1 of CGI-S or CGI-I score.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"score on a scale","timeFrame":"Baseline through Day 15","groups":[{"id":"OG000","title":"Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"OG001","title":"SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 mg, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"210"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.1","spread":"0.39"},{"groupId":"OG001","value":"-11.7","spread":"0.40"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0054","statisticalMethod":"MMRM","paramType":"LS Mean Difference","paramValue":"-1.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.7","ciUpperLimit":"-0.5","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.56","estimateComment":"Model used was the MMRM with treatment, baseline HAMD-17 total score, antidepressant use (SSRI/SNRI), assessment time point, and time point-by-treatment interaction as fixed effects with unstructured covariance structure."}]},{"type":"SECONDARY","title":"Change From Baseline in the HAMD-17 Total Score at Days 15 and 42","description":"The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. A negative change from baseline indicated improvement. LS mean was estimated using MMRM analysis. The missing values were imputed for the analysis.","populationDescription":"Full analysis set included all randomized participants who administered blinded IP with a valid baseline total score and at least 1 valid postbaseline total score in at least 1 of HAMD-17, HAM-A, MADRS, PHQ-9 or had a valid baseline and at least 1 valid postbaseline value in at least 1 of CGI-S or CGI-I score.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Days 15 and 42","groups":[{"id":"OG000","title":"Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"OG001","title":"SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 mg, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"210"}]}],"classes":[{"title":"Day 15","categories":[{"measurements":[{"groupId":"OG000","value":"-12.9","spread":"0.49"},{"groupId":"OG001","value":"-13.7","spread":"0.50"}]}]},{"title":"Day 42","categories":[{"measurements":[{"groupId":"OG000","value":"-14.9","spread":"0.56"},{"groupId":"OG001","value":"-14.9","spread":"0.56"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Day 15","nonInferiorityType":"SUPERIORITY","pValue":"0.2477","statisticalMethod":"MMRM","paramType":"LS Mean Difference","paramValue":"-0.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.2","ciUpperLimit":"0.6","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.70","estimateComment":"Model used was the MMRM with treatment, baseline HAMD-17 total score, antidepressant use (SSRI/SNRI), assessment time point, and time point-by-treatment interaction as fixed effects with unstructured covariance structure."},{"groupIds":["OG000","OG001"],"groupDescription":"Day 42","nonInferiorityType":"SUPERIORITY","pValue":"0.9248","statisticalMethod":"MMRM","paramType":"LS Mean Difference","paramValue":"-0.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.6","ciUpperLimit":"1.5","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.79","estimateComment":"Model used was the MMRM with treatment, baseline HAMD-17 total score, antidepressant use (SSRI/SNRI), assessment time point, and time point-by-treatment interaction as fixed effects with unstructured covariance structure."}]},{"type":"SECONDARY","title":"Change From Baseline in the HAMD-17 Total Score Around End of Blinded Treatment","description":"The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. A negative change from baseline indicated improvement. End of blinded treatment was defined as the average of change from baseline values of Days 12, 15 and 18. LS mean was estimated using MMRM analysis.","populationDescription":"Full analysis set included all randomized participants who administered blinded IP with a valid baseline total score and at least 1 valid postbaseline total score in at least 1 of HAMD-17, HAM-A, MADRS, PHQ-9 or had a valid baseline and at least 1 valid postbaseline value in at least 1 of CGI-S or CGI-I score.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"score on a scale","timeFrame":"Baseline, End of blinded treatment assessment (i.e., average of Days 12, 15 , and 18)","groups":[{"id":"OG000","title":"Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"OG001","title":"SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 mg, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"210"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.7","spread":"0.45"},{"groupId":"OG001","value":"-13.2","spread":"0.46"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4458","statisticalMethod":"MMRM","paramType":"LS Mean Difference","paramValue":"-0.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.8","ciUpperLimit":"0.8","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.65","estimateComment":"Model used was the MMRM with treatment, baseline HAMD-17 total score, antidepressant use (SSRI/SNRI), assessment time point, and time point-by-treatment interaction as fixed effects with unstructured covariance structure."}]},{"type":"SECONDARY","title":"Percentage of Participants With HAMD-17 Response at Day 15 and Day 42","description":"HAM-D response was defined as having a 50% or greater reduction from baseline in HAM-D total score. The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. Percentages were rounded off to the first decimal point.","populationDescription":"Full analysis set included all randomized participants who administered blinded IP with a valid baseline total score and at least 1 valid postbaseline total score in at least 1 of HAMD-17, HAM-A, MADRS, PHQ-9 or had a valid baseline and at least 1 valid postbaseline value in at least 1 of CGI-S or CGI-I score. Number analyzed is the number of participants with data available for analysis at the specified time points.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"At Days 15 and 42","groups":[{"id":"OG000","title":"Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"OG001","title":"SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 mg, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"210"}]}],"classes":[{"title":"Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49.2"},{"groupId":"OG001","value":"53.4"}]}]},{"title":"Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"177"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"65.3"},{"groupId":"OG001","value":"59.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Day 15","nonInferiorityType":"SUPERIORITY","pValue":"0.4946","statisticalMethod":"Binary Response Model","paramType":"Odds Ratio (OR)","paramValue":"1.15","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.78","ciUpperLimit":"1.69","estimateComment":"GEE for binary response model was used with factors for treatment, baseline HAMD-17 total score, antidepressant use (SSRI/SNRI), assessment time point, and time point-by-treatment interaction with unstructured covariance structure.","otherAnalysisDescription":"Generalized estimating equation is abbreviated as GEE in the method of estimation section."},{"groupIds":["OG000","OG001"],"groupDescription":"Day 42","nonInferiorityType":"SUPERIORITY","pValue":"0.3579","statisticalMethod":"Binary Response Model","paramType":"Odds Ratio (OR)","paramValue":"0.82","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.55","ciUpperLimit":"1.24","estimateComment":"GEE for binary response model was used with factors for treatment, baseline HAMD-17 total score, antidepressant use (SSRI/SNRI), assessment time point, and time point-by-treatment interaction with unstructured covariance structure."}]},{"type":"SECONDARY","title":"Percentage of Participants With HAMD-17 Remission at Day 15 and Day 42","description":"HAM-D remission was defined as having a HAM-D total score of ≤7. The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. Percentages were rounded off to the first decimal point.","populationDescription":"Full analysis set included all randomized participants who administered blinded IP with a valid baseline total score and at least 1 valid postbaseline total score in at least 1 of HAMD-17, HAM-A, MADRS, PHQ-9 or had a valid baseline and at least 1 valid postbaseline value in at least 1 of CGI-S or CGI-I score. Number analyzed is number of participants with data available for analysis at the specified time points.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 15 and 42","groups":[{"id":"OG000","title":"Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"OG001","title":"SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 mg, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"210"}]}],"classes":[{"title":"Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.8"},{"groupId":"OG001","value":"29.1"}]}]},{"title":"Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"177"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39.2"},{"groupId":"OG001","value":"37.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Day 15","nonInferiorityType":"SUPERIORITY","pValue":"0.1417","statisticalMethod":"Binary Response Model","paramType":"Odds Ratio (OR)","paramValue":"1.41","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.89","ciUpperLimit":"2.24","estimateComment":"GEE for binary response model was used with factors for treatment, baseline HAMD-17 total score, antidepressant use (SSRI/SNRI), assessment time point, and time point-by-treatment interaction with unstructured covariance structure."},{"groupIds":["OG000","OG001"],"groupDescription":"Day 42","nonInferiorityType":"SUPERIORITY","pValue":"0.7872","statisticalMethod":"Binary Response Model","paramType":"Odds Ratio (OR)","paramValue":"0.94","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.62","ciUpperLimit":"1.44","estimateComment":"GEE for binary response model was used with factors for treatment, baseline HAMD-17 total score, antidepressant use (SSRI/SNRI), assessment time point, and time point-by-treatment interaction with unstructured covariance structure."}]},{"type":"SECONDARY","title":"Change From Baseline in CGI-S Score at Day 15","description":"The CGI-S uses a 7-point Likert scale to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis. Considering total clinical experience, the investigator rated the participant on severity of mental illness at the time of rating as: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = extremely ill. A higher score indicated extreme illness. A negative change from baseline indicated improvement. LS mean was estimated using MMRM analysis.","populationDescription":"Full analysis set included all randomized participants who administered blinded IP with a valid baseline total score and at least 1 valid postbaseline total score in at least 1 of HAMD-17, HAM-A, MADRS, PHQ-9 or had a valid baseline and at least 1 valid postbaseline value in at least 1 of CGI-S or CGI-I score. Overall number of participants analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"score on a scale","timeFrame":"Baseline and Day 15","groups":[{"id":"OG000","title":"Active Comparator: Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"OG001","title":"Experimental: SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 mg, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"189"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"0.09"},{"groupId":"OG001","value":"-1.9","spread":"0.09"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1993","statisticalMethod":"MMRM","paramType":"LS Mean Difference","paramValue":"-0.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.4","ciUpperLimit":"0.1","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.13","estimateComment":"Model used was the MMRM with treatment, baseline CGI-S score, antidepressant use (SSRI/SNRI), assessment time point, and time point-by-treatment interaction as fixed effects with unstructured covariance structure."}]},{"type":"SECONDARY","title":"Percentage of Participants With CGI-I Response, at Day 3 and Day 15","description":"CGI-I response was defined as having a CGI-I score of \"very much improved\" or \"much improved.\" The CGI-I employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to IP. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. By definition, all CGI-I assessments are evaluated against baseline conditions. Higher scores indicated worse condition. Percentages were rounded off to the first decimal point.","populationDescription":"Full analysis set included all randomized participants who administered blinded IP with a valid baseline total score and at least 1 valid postbaseline total score in at least 1 of HAMD-17, HAM-A, MADRS, PHQ-9 or had a valid baseline and at least 1 valid postbaseline value in at least 1 of CGI-S or CGI-I score. Number analyzed is the number of participants with data available for analysis at the specified time points.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Days 3 and 15","groups":[{"id":"OG000","title":"Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"OG001","title":"SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 mg, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"210"}]}],"classes":[{"title":"Day 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"205"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.9"},{"groupId":"OG001","value":"22.9"}]}]},{"title":"Day 15","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"189"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54.3"},{"groupId":"OG001","value":"56.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Day 3","nonInferiorityType":"SUPERIORITY","pValue":"0.0079","statisticalMethod":"Binary Response Model","paramType":"Odds Ratio (OR)","paramValue":"2.05","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.21","ciUpperLimit":"3.47","estimateComment":"GEE for binary response model was used with factors for treatment, baseline CGI-S score, antidepressant use (SSRI/SNRI), assessment time point, and time point-by-treatment interaction with unstructured covariance structure."},{"groupIds":["OG000","OG001"],"groupDescription":"Day 15","nonInferiorityType":"SUPERIORITY","pValue":"0.6588","statisticalMethod":"Binary Response Model","paramType":"Odds Ratio (OR)","paramValue":"1.09","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.74","ciUpperLimit":"1.62","estimateComment":"GEE for binary response model was used with factors for treatment, baseline CGI-S score, antidepressant use (SSRI/SNRI), assessment time point, and time point-by-treatment interaction with unstructured covariance structure."}]},{"type":"SECONDARY","title":"Change From Baseline in MADRS Total Score at Day 15","description":"The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS total score was calculated as the sum of the 10 individual item scores. Each item yields a score of 0 (no symptoms) to 6 (symptoms of maximum severity). The total MADRS score (sum of all individual items) ranges from 0 (symptoms absent) to 60 (severe depression). Higher MADRS scores indicated more severe depression. A negative change from baseline indicated improvement. LS mean was estimated using MMRM analysis.","populationDescription":"Full analysis set included all randomized participants who administered blinded IP with a valid baseline total score and at least 1 valid postbaseline total score in at least 1 of HAMD-17, HAM-A, MADRS, PHQ-9 or had a valid baseline and at least 1 valid postbaseline value in at least 1 of CGI-S or CGI-I score. Overall number of participants analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"score on a scale","timeFrame":"Baseline and Day 15","groups":[{"id":"OG000","title":"Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"OG001","title":"SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 mg, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"188"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.9","spread":"0.75"},{"groupId":"OG001","value":"-17.2","spread":"0.76"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2322","statisticalMethod":"MMRM","paramType":"LS Mean Difference","paramValue":"-1.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.4","ciUpperLimit":"0.8","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"1.06","estimateComment":"Model used was the MMRM with treatment, baseline MADRS total score, antidepressant use (SSRI/SNRI), assessment time point, and time point-by-treatment interaction as fixed effects with unstructured covariance structure."}]},{"type":"SECONDARY","title":"Percentage of Participants With MADRS Response at Day 15","description":"MADRS response was defined as having a 50% or greater reduction from baseline in MADRS total score. The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS total score was calculated as the sum of the 10 individual item scores. Each item yields a score of 0 (no symptoms) to 6 (symptoms of maximum severity). The total MADRS score (sum of all individual items) ranges from 0 (symptoms absent) to 60 (severe depression). Higher MADRS scores indicated more severe depression. Percentages were rounded off to the first decimal point.","populationDescription":"Full analysis set included all randomized participants who administered blinded IP with a valid baseline total score and at least 1 valid postbaseline total score in at least 1 of HAMD-17, HAM-A, MADRS, PHQ-9 or had a valid baseline and at least 1 valid postbaseline value in at least 1 of CGI-S or CGI-I score. Overall number of participants analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 15","groups":[{"id":"OG000","title":"Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"OG001","title":"SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 mg, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"188"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.2"},{"groupId":"OG001","value":"51.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.5439","statisticalMethod":"Binary Response Model","paramType":"Odds Ratio (OR)","paramValue":"1.13","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.76","ciUpperLimit":"1.68","estimateComment":"GEE for binary response model was used with factors for treatment, baseline MADRS total score, antidepressant use (SSRI/SNRI), assessment time point, and time point-by-treatment interaction with unstructured covariance structure."}]},{"type":"SECONDARY","title":"Percentage of Participants With MADRS Remission at Day 15","description":"MADRS remission was defined as having a MADRS total score of ≤10. The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS total score was calculated as the sum of the 10 individual item scores. Each item yields a score of 0 (no symptoms) to 6 (symptoms of maximum severity). The total MADRS score (sum of all individual items) ranges from 0 (symptoms absent) to 60 (severe depression). Higher MADRS scores indicated more severe depression. Percentages were rounded off to the first decimal point.","populationDescription":"Full analysis set included all randomized participants who administered blinded IP with a valid baseline total score and at least 1 valid postbaseline total score in at least 1 of HAMD-17, HAM-A, MADRS, PHQ-9 or had a valid baseline and at least 1 valid postbaseline value in at least 1 of CGI-S or CGI-I score. Overall number of participants analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Day 15","groups":[{"id":"OG000","title":"Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"OG001","title":"SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 mg, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"188"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.4"},{"groupId":"OG001","value":"30.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7054","statisticalMethod":"Binary Response Model","paramType":"Odds Ratio (OR)","paramValue":"1.09","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.70","ciUpperLimit":"1.69","estimateComment":"GEE for binary response model was used with factors for treatment, baseline MADRS total score, antidepressant use (SSRI/SNRI), assessment time point, and time point-by-treatment interaction with unstructured covariance structure."}]},{"type":"SECONDARY","title":"Change From Baseline in HAM-A Total Score at Day 15","description":"Each of the 14 items in the HAM-A was defined by a series of symptoms, and measured both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints). The HAM-A total score was calculated as sum of the 14 individual item scores, each rated on a five point scale ranging from 0 (not present) to 4 (very severe). The total score (sum of all individual items) range from 0 to 56, where \\<17 indicated mild severity, 18 to 24 indicated mild to moderate severity, and 25 to 30 indicated moderate to severe severity. Higher scores indicated more severe disease. Negative change from baseline indicated improvement. LS mean was estimated using MMRM analysis.","populationDescription":"Full analysis set included all randomized participants who administered blinded IP with a valid baseline total score and at least 1 valid postbaseline total score in at least 1 of HAMD-17, HAM-A, MADRS, PHQ-9 or had a valid baseline and at least 1 valid postbaseline value in at least 1 of CGI-S or CGI-I score. Overall number of participants analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"score on a scale","timeFrame":"Baseline, Day 15","groups":[{"id":"OG000","title":"Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"OG001","title":"SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 mg, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"188"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.0","spread":"0.44"},{"groupId":"OG001","value":"-9.5","spread":"0.44"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4188","statisticalMethod":"MMRM","paramType":"LS Mean Difference","paramValue":"-0.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.7","ciUpperLimit":"0.7","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.62","estimateComment":"Model used was the MMRM with treatment, baseline HAM-A total score, antidepressant use (SSRI/SNRI), assessment time point, and time point-by-treatment interaction as fixed effects with unstructured covariance structure."}]},{"type":"SECONDARY","title":"Time to First HAMD-17 Response","description":"HAM-D response was defined as having a 50% or greater reduction from baseline in HAM-D total score. The 17-item HAM-D scale is used to assess the severity of depression. It is comprised of individual ratings related to following symptoms: depressed mood, feelings of guilt, suicide, insomnia, work and activities, retardation, agitation, anxiety, somatic symptoms, genital symptoms, hypochondriasis, loss of weight, and insight. Individual items are scored on either 3-point (0=none to 2=severe) or 5-point scale (0=none/absent to 4=most severe). Total score is the sum of individual items, ranging from 0 (not depressed) to 52 (severely depressed); where a higher score indicates more depression. Time (in days) from first dose of study drug to time of first HAMD response was reported in this outcome measure.","populationDescription":"Full analysis set included all randomized participants who administered blinded IP with a valid baseline total score and at least 1 valid postbaseline total score in at least 1 of HAMD-17, HAM-A, MADRS, PHQ-9 or had a valid baseline and at least 1 valid postbaseline value in at least 1 of CGI-S or CGI-I score.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"days","timeFrame":"From first dose of study drug up to first HAMD-17 response (up to approximately 65 days)","groups":[{"id":"OG000","title":"Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"OG001","title":"SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 mg, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"210"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","lowerLimit":"2","upperLimit":"50"},{"groupId":"OG001","value":"13","lowerLimit":"2","upperLimit":"61"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Depressive Symptoms at Day 15, as Assessed by PHQ-9","description":"The PHQ-9 is a participant-rated depressive symptom severity scale. The PHQ-9 total score is calculated as the sum of the 9 individual item scores. For individual items, scoring is based on responses to specific questions, as follows: 0 = not at all; 1 = several days; 2 = more than half the days; and 3 = nearly every day. The PHQ-9 possible total score range is 0 to 27, with higher scores reflecting greater depressive symptoms, and is categorized as follows: 0 to 4 = minimal depression, 5 to 9 = mild depression, 10 to 14 = moderate depression, 15 to 19 = moderately severe depression, and 20 to 27 = severe depression. Negative change from baseline indicated improvement. LS mean was estimated using MMRM analysis.","populationDescription":"Full analysis set included all randomized participants who administered blinded IP with a valid baseline total score and at least 1 valid postbaseline total score in at least 1 of HAMD-17, HAM-A, MADRS, PHQ-9 or had a valid baseline and at least 1 valid postbaseline value in at least 1 of CGI-S or CGI-I score. Overall number of participants analyzed is the number of participants with data available for analysis.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"score on a scale","timeFrame":"Baseline and Day 15","groups":[{"id":"OG000","title":"Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"OG001","title":"SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 mg, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"188"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.7","spread":"0.44"},{"groupId":"OG001","value":"-8.9","spread":"0.44"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.7758","statisticalMethod":"MMRM","paramType":"LS Mean Difference","paramValue":"-0.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.4","ciUpperLimit":"1.0","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.62","estimateComment":"Model used was the MMRM with treatment, baseline PHQ-9 total score, antidepressant use (SSRI/SNRI), assessment time point, and time point-by-treatment interaction as fixed effects with unstructured covariance structure."}]},{"type":"SECONDARY","title":"Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)","description":"An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE was defined as an AE with onset after the start of IP, or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study.","populationDescription":"Safety Set was defined as all participants who administered blinded IP.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Up to approximately 58 weeks","groups":[{"id":"OG000","title":"Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"OG001","title":"SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 mg, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"212"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.6"},{"groupId":"OG001","value":"74.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With TEAEs, Graded by Severity","description":"An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not related to the medicinal (investigational) product. A TEAE was defined as an AE with onset after the start of IP, or any worsening of a pre-existing medical condition/AE with onset after the start of IP and throughout the study. The severity was graded as mild, moderate and severe.","populationDescription":"Safety Set was defined as all participants who administered blinded IP.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Up to approximately 58 weeks","groups":[{"id":"OG000","title":"Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."},{"id":"OG001","title":"SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 mg, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"212"}]}],"classes":[{"title":"Mild","categories":[{"measurements":[{"groupId":"OG000","value":"38.1"},{"groupId":"OG001","value":"35.8"}]}]},{"title":"Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"25.2"},{"groupId":"OG001","value":"34.4"}]}]},{"title":"Severe","categories":[{"measurements":[{"groupId":"OG000","value":"2.3"},{"groupId":"OG001","value":"3.8"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to approximately 58 weeks","description":"The All-cause mortality is reported for all randomized participants and serious and other adverse events are reported for safety set that included all participants who administered blinded IP.","eventGroups":[{"id":"EG000","title":"Placebo + Assigned ADT","description":"Participants received SAGE-217-matching placebo capsules, orally, once daily aong with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily, from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42.","deathsNumAffected":0,"deathsNumAtRisk":220,"seriousNumAffected":0,"seriousNumAtRisk":218,"otherNumAffected":113,"otherNumAtRisk":218},{"id":"EG001","title":"SAGE-217 + Assigned ADT","description":"Participants received SAGE-217, 50 mg, orally, once daily along with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily, up to Day 42.","deathsNumAffected":0,"deathsNumAtRisk":220,"seriousNumAffected":2,"seriousNumAtRisk":212,"otherNumAffected":123,"otherNumAtRisk":212}],"seriousEvents":[{"term":"Seizure like phenomena","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":218},{"groupId":"EG001","numAffected":1,"numAtRisk":212}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":218},{"groupId":"EG001","numAffected":1,"numAtRisk":212}]}],"otherEvents":[{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":218},{"groupId":"EG001","numAffected":39,"numAtRisk":212}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":218},{"groupId":"EG001","numAffected":28,"numAtRisk":212}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":32,"numAtRisk":218},{"groupId":"EG001","numAffected":25,"numAtRisk":212}]},{"term":"Sedation","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":218},{"groupId":"EG001","numAffected":12,"numAtRisk":212}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":218},{"groupId":"EG001","numAffected":11,"numAtRisk":212}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":218},{"groupId":"EG001","numAffected":20,"numAtRisk":212}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":51,"numAtRisk":218},{"groupId":"EG001","numAffected":19,"numAtRisk":212}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":218},{"groupId":"EG001","numAffected":13,"numAtRisk":212}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":218},{"groupId":"EG001","numAffected":21,"numAtRisk":212}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":218},{"groupId":"EG001","numAffected":18,"numAtRisk":212}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (24.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":218},{"groupId":"EG001","numAffected":12,"numAtRisk":212}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Our agreement is subject to confidentiality but generally the PI can publish, for non-commercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication."},"pointOfContact":{"title":"US Biogen Clinical Trial Center","organization":"Biogen","email":"clinicaltrials@biogen.com","phone":"866-633-4636"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2022-01-10","uploadDate":"2023-08-25T09:59","filename":"Prot_000.pdf","size":9844723},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2022-01-11","uploadDate":"2023-08-25T09:59","filename":"SAP_001.pdf","size":1150212}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2023-09-22","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D003865","term":"Depressive Disorder, Major"}],"ancestors":[{"id":"D003866","term":"Depressive Disorder"},{"id":"D019964","term":"Mood Disorders"},{"id":"D001523","term":"Mental Disorders"}]},"interventionBrowseModule":{"meshes":[{"id":"C000634505","term":"zuranolone"},{"id":"D020280","term":"Sertraline"},{"id":"D000089983","term":"Escitalopram"},{"id":"D015283","term":"Citalopram"},{"id":"D000068736","term":"Duloxetine Hydrochloride"},{"id":"D000069468","term":"Desvenlafaxine Succinate"}],"ancestors":[{"id":"D015057","term":"1-Naphthylamine"},{"id":"D000588","term":"Amines"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D009281","term":"Naphthalenes"},{"id":"D011084","term":"Polycyclic Aromatic Hydrocarbons"},{"id":"D006841","term":"Hydrocarbons, Aromatic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D011083","term":"Polycyclic Compounds"},{"id":"D011437","term":"Propylamines"},{"id":"D009570","term":"Nitriles"},{"id":"D001572","term":"Benzofurans"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D013876","term":"Thiophenes"},{"id":"D013457","term":"Sulfur Compounds"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D003511","term":"Cyclohexanols"},{"id":"D000441","term":"Hexanols"},{"id":"D005233","term":"Fatty Alcohols"},{"id":"D000438","term":"Alcohols"},{"id":"D003510","term":"Cyclohexanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D010636","term":"Phenols"},{"id":"D001555","term":"Benzene Derivatives"},{"id":"D008055","term":"Lipids"}]}},"hasResults":true}